This is an expanded access program (EAP) for eligible participants. This program isdesigned to provide access to Elezanumab prior to approval by the local regulatoryagency. Availability will depend on territory eligibility. A medical doctor must decidewhether the potential benefit outweighs the risk of receiving an investigational therapybased on the individual patient's medical history and program eligibility criteria.